287 related articles for article (PubMed ID: 15366501)
1. [Mesalazine granules instead of tablets. New ulcerative colitis therapy confirmed also in general practice routine].
MMW Fortschr Med; 2004 Jun; 146(24):53. PubMed ID: 15366501
[No Abstract] [Full Text] [Related]
2. Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis--results from a randomized-controlled trial.
Raedler A; Behrens C; Bias P
Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1353-63. PubMed ID: 15606398
[TBL] [Abstract][Full Text] [Related]
3. [Ulcerative colitis. When is standard therapy enough?].
Stange EF
MMW Fortschr Med; 2000 Oct; 142(41):39-40. PubMed ID: 11085075
[No Abstract] [Full Text] [Related]
4. Encapsulated mesalamine granules (Apriso) for ulcerative colitis.
Med Lett Drugs Ther; 2009 May; 51(1312):38-9. PubMed ID: 19448588
[TBL] [Abstract][Full Text] [Related]
5. Accidentally ASCENDing into comparative effective research for inflammatory bowel disease.
Siegel CA
Gastroenterology; 2009 Dec; 137(6):1880-2. PubMed ID: 19879213
[No Abstract] [Full Text] [Related]
6. Comparison of the efficacy and safety of Eudragit-L-coated mesalazine tablets with ethylcellulose-coated mesalazine tablets in patients with mild to moderately active ulcerative colitis.
Gibson PR; Fixa B; Pekárková B; Bátovský M; Radford-Smith G; Tibitanzl J; Gabalec L; Florin TH; Greinwald R
Aliment Pharmacol Ther; 2006 Apr; 23(7):1017-26. PubMed ID: 16573804
[TBL] [Abstract][Full Text] [Related]
7. Treatment of distal ulcerative colitis: now the patients have the choice.
Schölmerich J
Ital J Gastroenterol Hepatol; 1999 Nov; 31(8):685-7. PubMed ID: 10730560
[No Abstract] [Full Text] [Related]
8. [Interstitial pneumonia related to mesalamine].
Lamsiah T; Moudden K; Baaj M; Hadri L
Gastroenterol Clin Biol; 2010 Mar; 34(3):224-6. PubMed ID: 20299168
[TBL] [Abstract][Full Text] [Related]
9. Combined oral and topical mesalazine treatment for extensive ulcerative colitis.
Moss AC; Cheifetz AS; Peppercorn MA
Nat Clin Pract Gastroenterol Hepatol; 2006 May; 3(5):290-3. PubMed ID: 16673009
[TBL] [Abstract][Full Text] [Related]
10. Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study.
Paoluzi OA; Iacopini F; Pica R; Crispino P; Marcheggiano A; Consolazio A; Rivera M; Paoluzi P
Aliment Pharmacol Ther; 2005 May; 21(9):1111-9. PubMed ID: 15854173
[TBL] [Abstract][Full Text] [Related]
11. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.
Dignass AU; Bokemeyer B; Adamek H; Mross M; Vinter-Jensen L; Börner N; Silvennoinen J; Tan G; Pool MO; Stijnen T; Dietel P; Klugmann T; Vermeire S; Bhatt A; Veerman H
Clin Gastroenterol Hepatol; 2009 Jul; 7(7):762-9. PubMed ID: 19375519
[TBL] [Abstract][Full Text] [Related]
12. [Intestinal mucosa as the focal point. In distal ulcerative colitis relief with topical therapy].
MMW Fortschr Med; 2004 Jun; 146(23):62-3. PubMed ID: 15373138
[No Abstract] [Full Text] [Related]
13. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis.
Kruis W; Jonaitis L; Pokrotnieks J; Mikhailova TL; Horynski M; Bátovský M; Lozynsky YS; Zakharash Y; Rácz I; Kull K; Vcev A; Faszczyk M; Dilger K; Greinwald R; Mueller R;
Aliment Pharmacol Ther; 2011 Feb; 33(3):313-22. PubMed ID: 21138455
[TBL] [Abstract][Full Text] [Related]
14. [Early renal failure caused by mesalazine].
Musil D
Vnitr Lek; 2000 Oct; 46(10):728-31. PubMed ID: 11344635
[TBL] [Abstract][Full Text] [Related]
15. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
Hanauer SB; Sandborn WJ; Kornbluth A; Katz S; Safdi M; Woogen S; Regalli G; Yeh C; Smith-Hall N; Ajayi F
Am J Gastroenterol; 2005 Nov; 100(11):2478-85. PubMed ID: 16279903
[TBL] [Abstract][Full Text] [Related]
16. Review article: increasing the dose of oral mesalazine therapy for active ulcerative colitis does not improve remission rates.
Safdi AV; Cohen RD
Aliment Pharmacol Ther; 2007 Nov; 26(9):1179-86. PubMed ID: 17944732
[TBL] [Abstract][Full Text] [Related]
17. [Once daily mesalazine for long-term remission. Ulcerative colitis: maintenance therapy becomes easier].
MMW Fortschr Med; 2008 Mar; 150(11):44-5. PubMed ID: 18447278
[No Abstract] [Full Text] [Related]
18. A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis.
Marakhouski Y; Fixa B; Holomán J; Hulek P; Lukas M; Bátovský M; Rumyantsev VG; Grigoryeva G; Stolte M; Vieth M; Greinwald R;
Aliment Pharmacol Ther; 2005 Jan; 21(2):133-40. PubMed ID: 15679762
[TBL] [Abstract][Full Text] [Related]
19. [Patients prefer foam].
MMW Fortschr Med; 2007 May; 149(21):48. PubMed ID: 17668735
[No Abstract] [Full Text] [Related]
20. MMX mesalamine.
Baker DE
Rev Gastroenterol Disord; 2006; 6(3):146-52. PubMed ID: 16957657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
